Gynecologic oncologyHumansFemaleCarcinosarcomaRetrospective StudiesAged
Efficacy and safety of pembrolizumab with or without lenvatinib in recurrent uterine carcinosarcoma: a real-world single-center study.
Seongyun Lim, Young Eun Chung, Jun-Hyeong Seo, Yooyoung Lee, Tae-Joong Kim, Jeong-Won Lee, Byoung-Gie Kim, Chel-Hun Choi
Published: 202610.1016/j.ygyno.2025.11.017
Abstract
OBJECTIVE: Uterine carcinosarcoma (UCS) is a rare, aggressive endometrial cancer with limited treatment options for recurrence. The role of immunotherapy in UCS remains unclear. This study aimed to evaluate the efficacy and safety of pembrolizumab wi…
Preview only. Read the full abstract at the source